Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans

Xu RUI-XIA; Zhang YAN; Guo YUAN-LIN; Ma CHUN-YAN; Yao YU-HONG; Li SHA; Li XIAO-LIN; Qing PING; Gao YING; Wu NA-QIONG; Zhu CHENG-GANG; Liu GENG; Dong QIAN; Sun JING; Li JIAN-JUN

Return

Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans

Author: Xu RUI-XIA ¹ ; Zhang YAN ¹ ; Guo YUAN-LIN ¹ ; Ma CHUN-YAN ¹ ; Yao YU-HONG ¹ ; Li SHA ¹ ; Li XIAO-LIN ¹ ; Qing PING ¹ ; Gao YING ¹ ; Wu NA-QIONG ¹ ; Zhu CHENG-GANG ¹ ; Liu GENG ¹ ; Dong QIAN ¹ ; Sun JING ¹ ; Li JIAN-JUN ¹
Author Information

1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
Publication Type:Journal Article
Keywords: XueZhiKang; Hyperlipidemia; Low-density lipoprotein cholesterol subfraction; Oxidized LDL; Interleukin-6
From: Chronic Diseases and Translational Medicine 2018;4(2):117-126
CountryChina
Language:English
Abstract: Background: Previous studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low-density lipoprotein cholesterol (LDL-C) and cardiovascular events. However, the mechanism of the effects of XZK on athero-sclerosis (AS) in humans has been reported less frequently. In the present study, we investigated the impact of XZK on lipoprotein subfractions, oxidized LDL (oxLDL), and interleukin-6 (IL-6). Methods: From October 2015 to July 2016, 40 subjects were enrolled in this study. Of them, 20 subjects with dyslipidemia received XZK 1200 mg/day for 8 weeks (XZK group); 20 additional healthy subjects who did not receive therapy acted as controls. The plasma lipoprotein subfractions, oxLDL, and IL-6 were examined at baseline and again at 8 weeks. Results: Data showed that XZK could significantly decrease not only plasma LDL-C levels (87.26 ± 24.45 vs. 123.34 ± 23.99, P<0.001), total cholesterol (4.14 ± 0.87 vs. 5.08 ± 1.03, P<0.001), triglycerides (0.95 ± 0.38 vs. 1.55 ± 0.61, P<0.05), and apolipoprotein B (1.70 ± 0.35 vs. 1.81 ± 0.72, P<0.05), but also oxLDL (36.36 ± 5.31 vs. 49.20 ± 15.01, P<0.05) and IL-6 (8.50 ± 7.40 vs. 10.40 ± 9.49, P<0.05). At the same time, XZK reduced the concentration of small LDL-C (1.78 ± 2.17 vs. 6.33 ± 7.78, P<0.05) and the percentage of the small LDL subfraction (1.09 ± 1.12 vs. 3.07 ± 3.09, P<0.05). Conclusions: Treatment with 1200 mg/day XZK for 8 weeks significantly decreased the atherogenic small LDL subfraction and reduced oxidative stress and inflammatory markers, in addition to affecting the lipid profile, suggesting multiple beneficial effects in coronary artery disease.